Launched on 6 October 2026Last updated on

Shock: type, resuscitation and vasopressors / inotropes

Separates the four types of shock in the ER and ICU: hypovolaemic or haemorrhagic, distributive (septic, anaphylactic, neurogenic), cardiogenic and obstructive (massive pulmonary embolism, tamponade, tension pneumothorax). The differential is ranked from the peripheries and JVP, the clinical context, bedside ultrasound by the RUSH protocol (Rapid Ultrasound in Shock and Hypotension: bedside echo for LV function, LVOT VTI with stroke volume and cardiac output, pericardial effusion with tamponade and RV dilatation; IVC diameter and collapsibility; lung ultrasound for B-lines and lung sliding; FAST free fluid and the aorta; compression ultrasound of the leg veins for DVT), the ECG and markers (lactate, troponin, BNP, procalcitonin), central venous saturation and the venous–arterial CO₂ gap, and shows MAP, shock index, cardiac power output and PAPi when entered. The passive leg raise reads fluid responsiveness (≥ 10% rise in cardiac output or VTI). Fluid resuscitation follows the type: 30 mL/kg balanced crystalloid within 3 h in sepsis (Surviving Sepsis Campaign 2021), blood products and tranexamic acid in haemorrhage, no fluid with congestion in cardiogenic shock, cautious volume in PE. The vasopressor and inotrope algorithm says which agent to prefer and which to avoid: norepinephrine first in septic and cardiogenic shock, vasopressin added at 0.25–0.5 µg/kg/min, hydrocortisone at ≥ 0.25 µg/kg/min for 4 h, dobutamine for low output, milrinone or levosimendan on β-blockers, IM adrenaline first in anaphylaxis, phenylephrine or vasopressin in LVOT obstruction, and dopamine discouraged (SOAP II). Cardiogenic shock adds the SCAI stage, immediate culprit-only revascularisation (SHOCK, CULPRIT-SHOCK), no routine IABP or VA-ECMO (IABP-SHOCK II, ECLS-SHOCK), a microaxial pump in selected STEMI shock (DanGer Shock), with ESC beside ACC/AHA, and why the ISCHEMIA trial does not apply. An adult infusion calculator gives the pump rate in mL/h from the usual vials made up to a 50 mL syringe, as in the paediatric inotropes.

Upload a report, lab sheet or echo picture to fill this calculator automatically.
Vital signs
Shock = hypotension (SBP < 90 or MAP < 65) and/or signs of hypoperfusion (lactate ≥ 2, cold skin, oliguria, confusion)
Bedside examination and context
Peripheries
Jugular venous pressure
POCUS: RUSH (Rapid Ultrasound in Shock and Hypotension)
Bedside echo, IVC, lung ultrasound, FAST and aorta, leg veins for DVT
Bedside echo: LV function and output
LV systolic function
IVC: diameter and collapsibility
IVC (by eye)
Lung ultrasound
Abdomen and aorta
Leg veins: DVT
ECG and markers
Passive leg raise (fluid responsiveness)
Trunk from 45° semi-recumbent to flat with legs at 45°; measure within 1 min. Reversible: no fluid given
Haemodynamics and saturations (optional)
Arterial and central lines, PA catheter or echo-derived output
Working diagnosis
Automatic from the findings, or choose the type to follow its plan
Type of shock
Enter the vital signs and mark the examination, POCUS and ECG findings.

Cardiogenic shock

SCAI shock stage
Suggested from the values above; tap to set it

Full staging with mortality: SCAI shock stages. Add the modifier A (cardiac arrest) and re-stage over time.

SCAI stage
A
At risk
AMI or HF, normal BP and perfusion
Decision guide
  • Monitor; treat the cause (reperfusion for AMI).
Recommendations in cardiogenic shock
ESC
  • Immediate coronary angiography and PCI of the infarct-related artery in cardiogenic shock complicating ACS
    IESC 2023 ACS
    Emergency CABG when the anatomy is not suitable for PCI.
  • Routine PCI of non-culprit lesions during primary PCI in cardiogenic shock is not recommended
    IIIESC 2023 ACS
    CULPRIT-SHOCK: culprit-only PCI lowered 30-day death or kidney replacement.
  • Routine IABP in ACS with cardiogenic shock without mechanical complications is not recommended
    IIIESC 2023 ACS
  • Short-term mechanical circulatory support may be considered in ACS with severe cardiogenic shock
    IIbESC 2023 ACS
  • Immediate ECG and echocardiography in suspected cardiogenic shock
    IESC 2021 HF
  • Inotropes for SBP < 90 mmHg with hypoperfusion; vasopressor (norepinephrine preferred) to raise BP
    IIbESC 2021 HF
  • Short-term MCS as bridge to recovery, decision, or transplant
    IIaESC 2021 HF
ACC/AHA
  • Emergency revascularisation of the culprit vessel in ACS with cardiogenic shock
    1ACC/AHA 2025 ACS
  • Routine PCI of non-culprit arteries at the time of primary PCI in cardiogenic shock is harmful
    3: HarmACC/AHA 2025 ACS
  • Microaxial flow pump (Impella CP) reasonable in selected STEMI with severe or refractory cardiogenic shock
    2aACC/AHA 2025 ACS
    DanGer Shock: lower 180-day death, more bleeding, limb ischaemia and kidney replacement; excludes comatose post-arrest patients and RV shock.
  • Routine IABP is not recommended
    3: No benefitACC/AHA 2025 ACS
  • Routine VA-ECMO in AMI cardiogenic shock is not recommended
    3: No benefitACC/AHA 2025 ACS
    ECLS-SHOCK: no mortality benefit, more bleeding and vascular complications.
  • Multidisciplinary shock team and haemodynamic (PA catheter) monitoring in refractory shock
    AHA 2017 · SCAI 2022
Key trials
  • SHOCK (1999): Early revascularisation in AMI shock: no 30-day difference but lower 6-month and long-term mortality (13% absolute at 6 years).
  • IABP-SHOCK II (2012): IABP did not lower 30-day or long-term mortality in AMI shock with early revascularisation.
  • CULPRIT-SHOCK (2017): Culprit-only PCI (staged non-culprit later) beat immediate multivessel PCI for 30-day death or kidney replacement.
  • SOAP II (2010): Dopamine vs norepinephrine: same mortality overall, more arrhythmias with dopamine and higher mortality in the cardiogenic subgroup.
  • ECLS-SHOCK (2023): Routine VA-ECMO in AMI shock with planned revascularisation: no 30-day survival gain, more bleeding.
  • DanGer Shock (2024): Impella CP in STEMI cardiogenic shock (lactate > 2.5, not comatose): lower 180-day death (45.8% vs 58.5%), more complications.
  • ISCHEMIA (2020): Initial conservative vs invasive strategy in stable CAD with moderate–severe ischaemia: excluded ACS, recent MI, LVEF < 35% and shock. Its conservative strategy does not apply to cardiogenic shock, where the culprit is revascularised at once.

Choosing a vasopressor or inotrope

AgentPrefer whenDiscouraged when
NorepinephrineFirst line in septic and cardiogenic shock; hypotension in PE, neurogenic and after haemorrhage control.Uncorrected hypovolaemia (as a substitute for volume).
VasopressinSecond agent in septic shock at norepinephrine 0.25–0.5 µg/kg/min; LVOT obstruction; pulmonary hypertension (spares PVR).Titration above 0.04 U/min (digital and mesenteric ischaemia).
EpinephrineAnaphylaxis (IM first); add-on in refractory septic shock; post-cardiac-surgery low output.First line in cardiogenic shock (OptimaCC: more refractory shock); raises lactate.
DobutamineLow output with an adequate MAP (cardiogenic, sepsis with LV dysfunction, PE with low output).LVOT obstruction; tachyarrhythmia; MAP < 65 without a vasopressor (vasodilates).
MilrinoneLow output in patients on β-blockers, RV failure with raised PVR.Hypotension without a vasopressor; kidney failure (accumulates); LVOT obstruction.
LevosimendanLow output on β-blockers; weaning from support.Septic shock (no benefit, SSC 2021); SBP < 85 mmHg; severe kidney or liver failure.
DopamineRarely: bradycardic shock with a low arrhythmia risk.Septic and cardiogenic shock (SOAP II: more arrhythmias, higher mortality in cardiogenic).
PhenylephrineLVOT obstruction (HCM), severe AS with vasodilation, anaesthesia-induced vasodilation, tachyarrhythmia limiting other agents.Low-output states (raises afterload, lowers CO); neurogenic bradycardia.

Infusion calculator: default vials

Adult doses. Press a drug for its pump rate: the usual vial is made up to a 50 mL syringe (levosimendan to a 500 mL bag); every amount is editable for your local concentration. Enter the weight in Vital signs above. Children: paediatric inotropes.

  • First line. Peripheral start through a large proximal vein is acceptable; move to a central line if running more than a few hours or at high dose.

    4 mg made up to 50 mL with glucose 5% (or glucose–saline): 80 µg/mL (0.08 mg/mL).

    Enter the weight above for the pump rate.

  • Raises lactate and heart rate (β2 effect); not a reason alone to stop.
  • Fixed dose 0.03 U/min, not titrated; above 0.04 U/min risks digital and mesenteric ischaemia. Not weight based.
  • Usual 2–10 µg/kg/min; tachyarrhythmia and vasodilation. Not with bicarbonate.
  • No routine loading dose (hypotension). Reduce in kidney impairment (CrCl < 50: 0.2–0.43 µg/kg/min). Precipitates with furosemide in the same line.
  • Infuse for 24 h; omit the 6–12 µg/kg load if SBP < 100. Effect lasts 7–9 days (active metabolite). Correct K⁺ first.
  • Discouraged (SOAP II): only for bradycardic shock with low arrhythmia risk. "Renal dose" has no benefit.
  • Pure α-agonist: LVOT obstruction, severe AS, anaesthetic vasodilation. Reflex bradycardia; lowers cardiac output in low-output states.
Print / Save PDF: opens the print dialog with a table of the inputs and result; choose Save as PDF to keep a file. Made on this device only; nothing is uploaded.
References
  1. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021;47:1181-1247.
  2. van Diepen S, Katz JN, Albert NM, et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017;136:e232-e268.
  3. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies. J Am Coll Cardiol 2022;79:933-946.
  4. Byrne RA, Rossello X, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44:3720-3826.
  5. Rao SV, O'Donoghue ML, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the management of patients with acute coronary syndromes. Circulation 2025;151:e771-e862.
  6. McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
  7. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock (SHOCK). N Engl J Med 1999;341:625-634.
  8. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock (IABP-SHOCK II). N Engl J Med 2012;367:1287-1296.
  9. Thiele H, Akin I, Sandri M, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock (CULPRIT-SHOCK). N Engl J Med 2017;377:2419-2432.
  10. Thiele H, Zeymer U, Akin I, et al. Extracorporeal life support in infarct-related cardiogenic shock (ECLS-SHOCK). N Engl J Med 2023;389:1286-1297.
  11. Møller JE, Engstrøm T, Jensen LO, et al. Microaxial flow pump or standard care in infarct-related cardiogenic shock (DanGer Shock). N Engl J Med 2024;390:1382-1393.
  12. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock (SOAP II). N Engl J Med 2010;362:779-789.
  13. Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction (OptimaCC). J Am Coll Cardiol 2018;72:173-182.
  14. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med 2020;382:1395-1407.
  15. Perera P, Mailhot T, Riley D, Mandavia D. The RUSH exam: Rapid Ultrasound in SHock in the evaluation of the critically ill. Emerg Med Clin North Am 2010;28:29-56.
  16. Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. Intensive Care Med 2016;42:1935-1947.
  17. Konstantinides SV, Meyer G, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J 2020;41:543-603.
  18. Adler Y, Charron P, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J 2015;36:2921-2964.
  19. Resuscitation Council UK. Emergency treatment of anaphylaxis: guidelines for healthcare providers. 2021.
  20. Walters BC, Hadley MN, Hurlbert RJ, et al. Guidelines for the management of acute cervical spine and spinal cord injuries: 2013 update. Neurosurgery 2013;60(Suppl 1):82-91.
  21. Arbelo E, Protonotarios A, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503-3626.